Blogs

Blogs

ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.

No Results.

Dr. Maher Saifo, an oncologist practicing in Syria, discusses how the Syrian war is affecting cancer care in a post written with his patient, Lama Meer Yousef. Together, they share their story of survival and hope against incredible odds.
Dr. Rita Saroufim, and Dr. Sarah Daouk, and I helped high school students put their science lessons into real-world context during a presentation on breast cancer awareness.
Hope springs eternal in the Brazilian economy and health care system, with cautious optimism for gains in oncology care.
Dr. Richard L. Schilsky outlines the Society's Target Agent and Profiling Utilization Registry (TAPUR) Study and similar international protocols. A global data sharing platform could greatly accelerate our ability to learn about new uses for currently approved targeted anticancer drugs.
Inequalities, especially in health care, breed discontent. We need better ways to continue incentivizing the development of new drugs while optimizing access. Biosimilars help, but they won't solve the whole problem.
Highlights from the 11th annual Best of ASCO Lebanon, attended by more than 300 medical professional from the country and surrounding region.
ASCO CEO Dr. Clifford Hudis describes the Society's Global Oncology programs and the initiatives of the Global Oncology Leadership Task Force. Dr. Hudis asks challenging questions about providing optimal cancer care in low-income countries. 
The region has seen structural reforms in health care systems, better training of cancer professionals, new initiatives for populations at high risk, expansion of cancer registries and cancer plans, and implementation of policies to improve prevention, early diagnosis, and treatment.
Follow-on biologics are here to stay, and represent enormous potential for patients with cancer being treated in low- and middle-income countries.
This is the story of how, like Mr. Smith in Washington, the medical community in Brazil gathered to speak truth to power about the lack of evidence for phosphoethanolamine as a cancer treatment.
Many issues and opportunities require the collective wisdom of the oncology community, but perhaps none are more challenging than those faced by many of our colleagues around the world, as the global burden of cancer will be magnified by the aging of the population.
A letter from Gabriel N. Hortobagyi, MD, FACP, FASCO, Chair of ASCO's Global Oncology Leadership Task Force.
I have had a wonderful experience working with ASCO’s International Cancer Corps to start the Bhutan cancer registry.
This is the story of how a populist Congress approved the medication that wasn't, and oncologists in the country are waiting to see if an enfeebled president will be able to veto the bill.
Reflecting on the challenges of delivering cancer care in regions rocked by hostilities, but seeing hope in impactful educational and scientific meetings such as the recent Beirut Breast Cancer Conference (BBCC-4).
This is the story of how an eager chemistry professor and a well-intended but misguided federal judge transformed cancer care and drug development in Brazil into a convoluted soap opera.
ASCO CEO Dr. Allen S. Lichter reflects on an optimistic approach to the challenges of providing high-quality cancer care around the globe on World Cancer Day.
Dr. Fredrick Chite Asirwa illustrates that every person in the clinic has an impact on patients.

Pages


Advertisement